Multidisciplinary Care Ensures ‘Comfort’ in Decisions Surrounding Lumpectomy for Breast Cancer Subtype, Says Expert

Video

Judy C. Boughey, MD, of Mayo Clinic in Rochester, Minnesota, details the multidisciplinary work that goes into delivering breast-conserving therapy for patients with multiple ipsilateral breast cancer.

During the 2022 San Antonio Breast Cancer Symposium (SABCS), CancerNetwork® spoke with Judy C. Boughey, MD, a surgical oncologist of the Division of Breast and Melanoma Surgical Oncology and the Department of Surgery at Mayo Clinic in Rochester, Minnesota, about the collaborative, multidisciplinary considerations that go into breast-conserving therapy for patients with multiple ipsilateral breast cancer.

According to Boughey, patients receiving breast conservation therapy will get the full value of a multidisciplinary team including breast surgeons, radiation oncologists, and medical oncologists.

Transcript:

All of breast cancer care these days is very much multidisciplinary. For these patients with multiple ipsilateral breast cancer, it does bring the value of a multidisciplinary team’s input into that patient's care. If the patient chooses to proceed with breast-conserving therapy, that's going to involve not only surgical resection, but also the incorporation of adjuvant whole breast radiation.

We want to make sure that the patient and the radiation oncologists are comfortable proceeding with the radiation aspects, and then also to incorporate the medical oncologist in terms of the systemic therapy recommendations.

Reference

Boughey JC, Rosenkranz KM, Ballman KV, et al. Impact of breast conservation therapy on local recurrence in patients with multiple ipsilateral breast cancer – results from ACOSOG Z11102 (Alliance). Presented at the 2022 San Antonio Breast Cancer Symposium; December 6-10, 2022; San Antonio, TX; abstract GS4-01.

Related Videos
Collaboration among nurses, social workers, and others may help in safely administering outpatient bispecific T-cell engager therapy to patients.
Immunotherapy may be an “elegant” method of managing colorectal cancer, says Gregory Charak, MD.
D. Ross Camidge, MD, PhD, spoke about how the approval of alectinib is the beginning of multiple other approvals for patients with ALK-positive NSCLC.
Nurses should be educated on cranial nerve impairment that may affect those with multiple myeloma who receive cilta-cel, says Leslie Bennett, MSN, RN.
Treatment with cilta-cel may give patients with multiple myeloma “more time,” according to Ishmael Applewhite, BSN, RN-BC, OCN.
Nurses may need to help patients with multiple myeloma adjust to walking differently in the event of peripheral neuropathy following cilta-cel.
Administering neoadjuvant therapy to patients with colorectal cancer may help surgical oncologists attain a negative-margin resection.
Increasing screening for younger individuals who are at risk of colorectal cancer may help mitigate the rising early incidence of this disease.
Laparoscopy may reduce the degree of pain or length of hospital stay compared with open surgery for patients with colorectal cancer.
The use of proton therapy may offer a more specific depth charge compared with conventional radiation, according to Timothy Chen, MD.